Upgrade to SI Premium - Free Trial

Madrigal Pharma (MDGL)

488.96 -3.87 (0.79%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/11/26)

Latest Headlines

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) June 4, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 June 3, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) Reiterated at Market Outperform by Citizens June 1, 2026 4:42 AM - StreetInsider Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH May 27, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) May 21, 2026 4:05 PM - Globe NewsWire Madrigal to present Rezdiffra data at EASL 2026 conference May 20, 2026 8:01 AM - StreetInsider Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk May 20, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Raised to $709 at Truist Securities May 13, 2026 6:16 AM - StreetInsider Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) May 7, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Lowered to $578 at Canaccord May 7, 2026 6:39 AM - StreetInsider Madrigal Pharma (MDGL) Tops Q1 EPS by 94c May 6, 2026 7:08 AM - StreetInsider Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates May 6, 2026 7:00 AM - Globe NewsWire Arrowhead licenses liver disease drug to Madrigal for $25 million upfront May 5, 2026 8:03 AM - StreetInsider Madrigal licenses siRNA asset from Arrowhead for MASH treatment May 5, 2026 8:01 AM - StreetInsider Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline May 5, 2026 8:00 AM - Globe NewsWire Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals May 5, 2026 8:00 AM - BizWire Madrigal Pharmaceuticals (MDGL) PT Raised to $536 at BofA Securities April 30, 2026 9:10 AM - StreetInsider Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 April 22, 2026 8:01 AM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) April 21, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Raised to $656 at UBS April 14, 2026 9:47 AM - StreetInsider Bernstein on US Pharma and Biotech: Who might buy whom? April 13, 2026 5:52 AM - StreetInsider Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) April 7, 2026 4:06 PM - Globe NewsWire Wolfe Research comments on Madrigal Pharmaceuticals (MDGL) M&A optimism 'makes strategic sense' for buyers April 1, 2026 12:38 PM - StreetInsider Increasing unusual option volume: PROP CORN AUTL TERN VFS WTI CANE MDGL March 31, 2026 9:50 AM - StreetInsider Madrigal Pharmaceuticals (MDGL) PT Raised to $652 at Evercore ISI March 20, 2026 8:15 AM - StreetInsider Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) March 19, 2026 4:05 PM - Globe NewsWire Full Article List